By utilizing the proprietary microbial strains and synthetic biology technology transferred from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), we are currently developing a high-efficiency mass-production process for KGF-1 to enable future industrialization. KGF-1 is a potent signaling protein that specifically targets epithelial cells to stimulate rapid regeneration, making it highly effective for wound healing and skin barrier reinforcement. Our ongoing R&D focuses on optimizing this microbial platform to ensure superior bioactivity and scalability, aiming to provide a high-purity regenerative solution for the medical and skincare markets.